. 2022 Mar 19;3(4):100309. doi: 10.1016/j.jtocrr.2022.100309

Table 1.

Study Characteristics

Study	Country	Study Design	Treatment Period	No.of Patient	Male, %	Mean Age (y)	Initial ICI
							Regimen(i)	Therapy Line	TPS ≥ 50% (%)^a	PFSi (M)	Best Response					G3/4 IrAE	Cessation Reason
							Regimen(i)	Therapy Line	TPS ≥ 50% (%)^a	PFSi (M)	CR	PR	Stable Disease	PD	NR	G3/4 IrAE	Cessation Reason
Bernard et al., 2018¹³	France	Retrospective	2012.5–2017.10	1	NR	NR	Anti–PD-(L)1	NR	NR	19.9	0	1	0	0	0	0	PD
Fujita et al., 2018¹⁴	Japan	Retrospective	2015.12–2018.3	12	66.7	70.8	Nivo	Second∼	41.7	6.2	0	7	2	3	0	2	PD
Niki et al., 2018¹⁵	Japan	Retrospective	2015.12–2017.12	11	81.8	66	Nivo	NR	NR	4.9	0	5	2	4	0	0	PD
Santini et al., 2018¹⁶	America	Retrospective	2011.4–2016.5	38	52.6	64	Anti–PD(L)1/anti-CTLA4	First∼	NR	NR	18		20		0	6	irAE
Fujita et al., 2019¹⁷	Japan	Retrospective	2018.1–2018.12	18	61.1	71	Nivo/Pemb	Second	50	NR	0	8	4	5	1	0	NR
Watanabe et al., 2019¹⁸	Japan	Retrospective	2015.12–2017.12	14	57.1	61.5	Atezo/nivo/pemb	NR	50	3.7	0	3	5	6	0	0	PD
Mouri et al., 2019¹⁹	Japan	Retrospective	2015.12–2018.8	21	90.5	69.6	Nivo	Second∼	NR	13.3	1	12	8	0	0	7	irAE
Fujita et al., 2020²⁰	Japan	Retrospective	2018.1–2019.8	15	93.3	71.4	Atezo/durva	Second∼	0	3	0	0	5	9	1	0	PD
Gobbini et al., 2020²¹	France	Retrospective	2010–2018	144	67.4	63	Anti–PD-(L)1	First∼	14.6	13	10	61	38	26	9	27	irAE, PD, clinical decision
Herbst et al., 2020²²	Keynote 10	Retrospective	2013.8–2015.2	14	NR	NR	Pemb	First∼	NR	NR	0	13	0	0	1	NR	Clinical decision
Katayama et al., 2020²³	Japan	Retrospective	2017.4–2018.11	35	68.6	70	Nivo/pemb/atezo	Third	40	4	0	12	12	10	1	NR	PD
Kitagawa et al., 2020²⁴	Japan	Retrospective	2018.4–2019.9	17	64.7	69	Anti–PD-(L)1	First∼	17.6	9.7	0	6	9	2	0	3	PD
Furuya et al., 2021²⁵	Japan	Retrospective	2018.4–2019.2	38	NR	NR	Nivo/pemb	Second∼	NR	NR	0	8	16	11	3	NR	irAE, PD
Takahara et al., 2022²⁶	Japan	Retrospective	2016.8–2021.7	24	66.7	NR	Durva/pemb/nivo	NR	45.8	NR	NR					4	irAE, PD
Xu et al., 2022²⁷	People's Republic of China	Retrospective	2018.12–2021.6	40	77.5	NR	Anti–PD-1	NR	NR	5.7	0	14	19	7	0	NR	PD

Study	Interval Time (Median mo)	ICI Rechallenge
		Regimen(r)	Therapy Line	TPS ≥ 50% (%)^a	PFSr (M)	Best Response					G3/4 irAE
		Regimen(r)	Therapy Line	TPS ≥ 50% (%)^a	PFSr (M)	CR	PR	Stable Disease	PD	NR	G3/4 irAE
Bernard et al., 2018¹³	10	Anti–PD-(L)1	NR	NR	35.4	0	0	1	0	0	0
Fujita et al., 2018¹⁴	NR	Pemb	NR	50	3.1	0	1	4	6	1	0
Niki et al., 2018¹⁵	4.2	Nivo/pemb	NR	NR	2.7	0	3	2	6	0	0
Santini et al., 2018¹⁶	NR	Anti–PD-(L)1/anti–CTLA4	NR	NR	NR	NR					8
Fujita et al., 2019¹⁷	NR	Atezo	Third∼	NR	NR	0	0	7	11	0	2
Watanabe et al., 2019¹⁸	6.5	Atezo/nivo/pemb	NR	NR	1.6	0	1	2	11	0	0
Mouri et al., 2019¹⁹	NR	Nivo	NR	NR	7.4	0	4	14	2	1	2
Fujita et al., 2020²⁰	NR	Nivo/pemb	NR	NR	2.4	0	0	4	9	2	2
Gobbini et al., 2020²¹	NR	Anti–PD-(L)1	Second∼	NR	4.4	5	18	45	54	22	4
Herbst et al., 2020²²	NR	Pemb	NR	NR	NR	0	6	5	2	1	NR
Katayama et al., 2020²³	5.2	Nivo/pemb/atezo	Fourth	NR	2.7	0	1	14	18	2	NR
Kitagawa et al., 2020²⁴	NR	Anti–PD-(L)1	Second∼	NR	4	0	1	9	7	0	2
Furuya et al., 2021²⁵	NR	Atezo	NR	NR	NR	0	1	12	20	5	NR
Takahara et al., 2022²⁶	NR	Nivo/atezo/pemb	NR	NR	NR	0	2	9	13	0	3
Xu et al., 2022²⁷	NR	Anti–PD-1	NR	NR	6.8	0	9	25	6	0	NR

Anti–PD-(L)1, immune checkpoint blockade targeting programmed cell death-(ligand)1; Atezo, atezolizumab; CR, complete response; Durva, durvalumab; G3/4 irAE, grade 3/4 immune-related adverse event; ICI, immune checkpoint inhibitor; Nivo, nivolumab; NR, not reported; PD, progressive disease; Pemb, pembrolizumab; PFSi, progression-free survival of initial ICI; PFSr, progression-free survival of ICI rechallenge; PR, partial response; Regimen(i), initial ICI regimen; Regimen(r), ICI rechallenge regimen; TPS, tumor proportion score.

Percentage of patients whose TPS is equals to or more than 50%.